Evaluation of Boosted and Unboosted Atazanavir Plasma Concentration in HIV Infected Patients

ISSN: 1873-4251 (Online)
ISSN: 1570-162X (Print)


Volume 12, 6 Issues, 2014


Download PDF Flyer




Current HIV Research

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 23rd of 34 in Virology
  • 48th of 70 in Infectious Diseases
  • 102th of 137 in Immunology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Charles Wood
University of Nebraska
Lincoln, NE
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.033
5 - Year: 1.941

Evaluation of Boosted and Unboosted Atazanavir Plasma Concentration in HIV Infected Patients

Author(s): Silvia Amadasi, Silvia Odolini, Emanuele Foca, Annafranca Panzali, Carlo Cerini, Lucia Lonati, Maria C. Pezzoli, Paola Nasta, Salvatore Casari, Francesco Castelli and Eugenia Quiros-Roldan

Affiliation: University Division of Infectious and Tropical Diseases, University of Brescia, P.le Spedali Civili, 1 - 25123 Brescia, Italy.

Abstract

Objectives: The aim of the study was to identify variables that can influence atazanavir plasma concentration.

Methods: We retrospectively analysed atazanavir trough concentration of HIV infected patients who performed therapeutic drug monitoring between October 2007 and July 2011. Qualitative variables were compared with X2 test while continuous ones with Mann-Whitney and Student’s t-test. A linear regression model was used to investigate factors influencing atazanavir plasma concentration. Therefore, we analysed the impact of cirrhosis on atazanavir pharmacokinetic variability.

Results: 255 plasma samples from 179 patients were analysed. At the univariate analysis female gender (+144.4 ng/mL; p=0.05) and tenofovir (+196.8 ng/mL; p=0.002) were associated with higher atazanavir concentrations. The multivariate model confirmed these two variables (+164.6 ng/mL; p=0.02 and +150.4 ng/mL; p=0.01) as independently associated with higher atazanavir trough concentration. The analysis of cirrhotic population showed an influence of tenofovir (-255.9 ng/mL; p=0.01), increased AST (+95.3 ng/mL; p=0.09), ALT (+67.9 ng/mL; p=0.07) and creatinine (+517.2 ng/mL; p=0.04). The multivariate model confirm that tenofovir was associated with lower atazanavir trough concentration (-284.1 ng/mL; p=0.005) while AST values significantly increased atazanavir concentrations (+114.5 ng/mL; p=0.03).

Discussion: Atazanavir is a safe and manageable drug. Our results suggest that female patients tend to have higher atazanavir plasma concentration, while the effect of tenofovir needs to be better clarified.


Keywords: Atazanavir, cirrhosis, HIV, pharmacokinetics, therapeutic drug monitoring, trough concentration.

Download Free Rights and Permissions

Article Details

Volume: 11
Issue Number: 8
First Page: 642
Last Page: 646
Page Count: 5
DOI: 10.2174/1570162X12666140207162225
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science